CHINA BIOTECH SERVICES HOLDINGS LIMITED
中國生物科技服務控股有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock code: 8037)

ANNUAL RESULTS ANNOUNCEMENT
FOR THE YEAR ENDED 31 DECEMBER 2025

CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE")

GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration.

Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

*This announcement, for which the directors (the "**Directors**") of China Biotech Services Holdings Limited (the "**Company**") collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM (the "**GEM Listing Rules**") for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

FINAL RESULTS

The board of Directors ("**Board**") of the Company is pleased to announce the final results of the Company and its subsidiaries (collectively, the "**Group**") for the year ended 31 December 2025, together with the comparative figures for the year ended 31 December 2024. The final consolidated results of the Group have been reviewed by the audit committee of the Company (the "**Audit Committee**").

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	**2025** *HK$'000*	2024 *HK$'000*
Revenue	*4*	**73,503**	70,509
Cost of sales		**(65,777)**	(75,449)
Gross profit/(loss)		**7,726**	(4,940)
Other income and other gains, net	*5*	**23,558**	5,800
Reversal of/(allowance for) impairment loss on financial assets, net		**30**	(684)
Selling and distribution expenses		**(8,314)**	(11,774)
Research and development cost		**(17,201)**	(33,309)
Administrative expenses		**(58,129)**	(98,141)
Loss from operations		**(52,330)**	(143,048)
Finance costs	*7*	**(19,473)**	(16,922)
Fair value loss on convertible bonds	*13*	**(3,163)**	(24,156)
Impairment loss on right-of-use assets		**(6,731)**	(2,584)
Impairment loss on property, plant and equipment	*5(b)*	**–**	(52,713)
Impairment loss on intangible assets		**–**	(13,374)
Loss before tax		**(81,697)**	(252,797)
Income tax credit	*8*	**856**	943
Loss for the year	*9*	**(80,841)**	(251,854)
Loss for the year attributable to:			
Owners of the Company		**(68,778)**	(198,146)
Non-controlling interests		**(12,063)**	(53,708)
		(80,841)	(251,854)

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2025

	Note	**2025**	2024
		HK$'000	*HK$'000*
Loss for the year		**(80,841)**	(251,854)
Other comprehensive loss after tax:			
Item that will not be reclassified to profit or loss:			
Fair value change of financial assets at fair value through other comprehensive income ("**FVOCI**")		**(12,569)**	(10,308)
Item that may be reclassified to profit or loss:			
Exchange differences on translating foreign operations		**8,039**	(6,820)
Other comprehensive loss for the year, net of tax		**(4,530)**	(17,128)
Total comprehensive loss for the year		**(85,371)**	(268,982)
Total comprehensive loss for the year attributable to:			
Owners of the Company		**(73,532)**	(214,971)
Non-controlling interests		**(11,839)**	(54,011)
		(85,371)	(268,982)
Loss per share for loss attributable to owners of the Company	*11*		
Basic and diluted *(HK$)*		**(7.0) cents**	(20.5) cents

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT 31 DECEMBER 2025

	Note	2025 HK$'000	2024 HK$'000
ASSETS			
Non-current assets			
Property, plant and equipment		**384,711**	219,341
Right-of-use assets		**17,233**	15,996
Goodwill		**108,837**	103,894
Intangible assets		**31,765**	34,944
Financial assets at FVOCI		**30,660**	43,229
Deposit and prepayment	*12*	**49,680**	49,456
Total non-current assets		**622,886**	466,860
Current assets			
Inventories		**36,939**	3,971
Trade and other receivables, deposits and prepayment	*12*	**30,641**	25,416
Tax recoverable		**26**	80
Pledged bank deposits		**–**	14,715
Bank and cash balances		**12,083**	18,913
Total current assets		**79,689**	63,095
TOTAL ASSETS		**702,575**	529,955

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT 31 DECEMBER 2025

	Note	**2025**	2024
	Note	***HK$'000***	*HK$'000*
EQUITY			
Equity attributable to owners of the Company			
Share capital		**97,573**	97,573
Other reserves		**93,837**	167,369
		191,410	264,942
Non-controlling interests		**(35,665)**	(22,554)
Total equity		**155,745**	242,388
LIABILITIES			
Non-current liabilities			
Convertible bonds	*13*	**–**	41,635
Derivative financial liabilities	*13*	**–**	6,002
Lease liabilities		**5,662**	1,793
Written put option liability	*14*	**49,275**	40,480
Borrowings	*16*	**142,081**	–
Deferred tax liabilities		**4,054**	5,043
Total non-current liabilities		**201,072**	94,953
Current liabilities			
Trade and other payables and accruals	*15*	**89,041**	48,093
Convertible bonds	*13*	**44,268**	–
Derivative financial liabilities	*13*	**9,165**	–
Lease liabilities		**6,958**	5,711
Borrowings	*16*	**195,931**	138,693
Current tax liabilities		**395**	117
Total current liabilities		**345,758**	192,614
Total liabilities		**546,830**	287,567
TOTAL EQUITY AND LIABILITIES		**702,575**	529,955

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

	Attributable to owners of the Company											
	Share capital *HK$'000*	Share premium *HK$'000*	Share-based payments reserve *HK$'000*	Special reserve *HK$'000*	Shares held under share award scheme *HK$'000*	Other reserves *HK$'000*	Financial assets at FVOCI reserve *HK$'000*	Foreign currency translation reserve *HK$'000*	Accumulated losses *HK$'000*	Sub-total *HK$'000*	Non-controlling interests *HK$'000*	Total equity *HK$'000*
At 1 January 2024	96,323	490,692	6,502	212,948	(6,622)	6,488	(18,000)	(14,779)	(310,798)	462,754	27,972	490,726
Total comprehensive loss for the year	–	–	–	–	–	–	(10,308)	(6,517)	(198,146)	(214,971)	(54,011)	(268,982)
Transfer upon disposal	–	–	–	–	–	–	32,329	–	(32,329)	–	–	–
Share-based payments	–	–	304	–	–	–	–	–	–	304	–	304
Lapse of share options	–	–	(6,806)	–	–	–	–	–	6,806	–	–	–
Deemed disposal of shares of subsidiaries	–	–	–	–	–	12,115	–	–	–	12,115	3,975	16,090
Dividend paid to non-controlling shareholders of a subsidiary	–	–	–	–	–	–	–	–	–	–	(490)	(490)
Shares issued under placing	1,250	3,750	–	–	–	–	–	–	–	5,000	–	5,000
Less: Share issued expenses	–	(260)	–	–	–	–	–	–	–	(260)	–	(260)
Changes in equity for the year	1,250	3,490	(6,502)	–	–	12,115	22,021	(6,517)	(223,669)	(197,812)	(50,526)	(248,338)
At 31 December 2024	97,573	494,182	–	212,948	(6,622)	18,603	4,021	(21,296)	(534,467)	264,942	(22,554)	242,388

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

	Attributable to owners of the Company											
	Share capital *HK$'000*	Share premium *HK$'000*	Share-based payments reserve *HK$'000*	Special reserve *HK$'000*	Shares held under share award scheme *HK$'000*	Other reserves *HK$'000*	Financial assets at FVOCI reserve *HK$'000*	Foreign currency translation reserve *HK$'000*	Accumulated losses *HK$'000*	Sub-total *HK$'000*	Non-controlling interests *HK$'000*	Total equity *HK$'000*
At 1 January 2025	**97,573**	**494,182**	**-**	**212,948**	**(6,622)**	**18,603**	**4,021**	**(21,296)**	**(534,467)**	**264,942**	**(22,554)**	**242,388**
Total comprehensive loss for the year	-	-	-	-	-	-	(12,569)	7,815	(68,778)	(73,532)	(11,839)	(85,371)
Dividend paid to non-controlling shareholders of a subsidiary	-	-	-	-	-	-	-	-	-	-	(1,272)	(1,272)
Changes in equity for the year	-	-	-	-	-	-	(12,569)	7,815	(68,778)	(73,532)	(13,111)	(86,643)
At 31 December 2025	**97,573**	**494,182**	**-**	**212,948**	**(6,622)**	**18,603**	**(8,548)**	**(13,481)**	**(603,245)**	**191,410**	**(35,665)**	**155,745**

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1. GENERAL INFORMATION

China Biotech Services Holdings Limited and its subsidiaries are principally engaged in the provision of medical laboratory testing services and health check services in Hong Kong, provision of tumor immune cell therapy and health management services in the People's Republic of China (the "**PRC**"), provision of boron neutron capture therapy ("**BNCT**") services in the PRC, sales and distribution of health related and pharmaceutical products in the PRC and Hong Kong and provision of insurance brokerage services in Hong Kong.

The Company is a limited liability company incorporated in the Cayman Islands on 5 June 2003 and continued in Bermuda on 29 August 2013. The address of its registered office is Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda and the address of its principal place of business in Hong Kong is Suites 1904-05A, 19/F, Sino Plaza, 255-257 Gloucester Road, Causeway Bay, Hong Kong.

The Company is listed on GEM of the Stock Exchange.

2. BASIS OF PREPARATION

These consolidated financial statements have been prepared in accordance with HKFRS Accounting Standards issued by the Hong Kong Institute of Certified Public Accountants (the "**HKICPA**"). HKFRS Accounting Standards comprise Hong Kong Financial Reporting Standards ("**HKFRS**"); Hong Kong Accounting Standards ("**HKAS**"); and Interpretations. These consolidated financial statements also comply with the applicable disclosure provisions of the Rules Governing the Listing of Securities on GEM of the Stock Exchange and with the disclosure requirements of the Hong Kong Companies Ordinance (Cap. 622).

The HKICPA has issued certain new and revised HKFRS Accounting Standards that are first effective or available for early adoption for the current accounting period of the Group. Note 3 provides information on any changes in accounting policies resulting from initial application of these developments to the extent that they are relevant to the Group for the current and prior accounting periods reflected in these consolidated financial statements.

The Group incurred a loss of approximately HK$80,841,000 during the year ended 31 December 2025 and, as of that date, the Group's current liabilities exceeded its current assets by approximately HK$266,069,000. As at 31 December 2025, the Group had total borrowings and lease liabilities of approximately HK$338,012,000 and approximately HK$12,620,000 respectively, while the Group had bank and cash balances of approximately HK$12,083,000.

In the opinion of the Directors of the Company after taking the following matters into consideration, the Group will have sufficient working capital to finance its operations and to meet its financial obligations as and when they fall due in the foreseeable future, based on the cash flow projections of the Group covering a period of eighteen months up to 30 June 2027 (the "**Forecast Period**"):

(i) As at the date of approval of the consolidated financial statements for the year ended 31 December 2025, the Group has obtained proceeds of US$35,000,000 (equivalent to HK$272,440,000) from the issuance of convertible bonds to Wealth Strategy Holding Limited (the "**Subscriber**"). On 29 December 2025, the Company and the Subscriber entered into a subscription agreement in respect of subscription of US$35,000,000 convertible bonds of the Company by the Subscriber. The convertible bonds are repayable in 4 years and the issuance of convertible bonds was completed on 20 February 2026.

(ii) The Group will substantially improve its cash flow position by generating operating cash inflows in the BNCT segment from the provision of BNCT services in the Forecast Period after the commencement of trial operation of BNCT cancer treatment center in the first quarter of 2026.

The directors of the Company are of the opinion that, taking into account the above-mentioned plans and measures, the Group will have sufficient working capital to sustain its operations and meet its financial obligations as and when they fall due in the foreseeable future. Accordingly, the directors are of the opinion that it is appropriate to prepare the consolidated financial statements of the Group for the year ended 31 December 2025 on a going concern basis.

3. ADOPTION OF NEW AND REVISED HKFRS ACCOUNTING STANDARDS

(a) Changes in accounting policies and disclosures

The Group has adopted amendments to HKAS 21 Lack of Exchangeability for the first time for the current year's financial statements. The Group has not early adopted any other standard or amendment that has been issued but is not yet effective.

Amendments to HKAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted in and the functional currencies of overseas subsidiaries for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the Group's financial statements.

In addition, the HKICPA has issued amendments to Illustrative Examples on HKFRS 7, HKFRS 18, HKAS 1, HKAS 8, HKAS 36 and HKAS 37 Disclosures about Uncertainties in the Financial Statements, which added illustrative examples in the corresponding HKFRS Accounting Standards. These examples reflect existing requirements in the corresponding HKFRS Accounting Standards to report the effects of uncertainties in the financial statements using climate-related examples. Therefore, the amendments do not have an effective date or transitional provisions. The Group has considered the guidance in these illustrative examples which has had no significant impact on the Group's financial statements.

(b) Revised HKFRS Accounting Standards in issue but not yet effective

Up to the date of issue of these consolidated financial statements, the HKICPA has issued a number of new standards and amendments to standards and interpretation, which are not effective for the year ended 31 December 2025 and which have not been adopted in these financial statements. The Group has not early applied the following which may be relevant to the Group.

	Effective for accounting periods beginning on or after
Amendments to HKFRS 9 and HKFRS 7 – Classification and Measurement of Financial Instruments	1 January 2026
Amendments to HKFRS 9 and HKFRS 7 – Contracts Referencing Nature-dependent Electricity	1 January 2026
Annual Improvements to HKFRS Accounting Standards – Volume 11	1 January 2026
HKFRS 18 – Presentation and Disclosure in Financial Statements	1 January 2027
HKFRS 19 – Subsidiaries without Public Accountability: Disclosures	1 January 2027
Amendments to HK Int 5 – Presentation of Financial Statements – Classification by the Borrower of a Term Loan that Contains a Repayment on Demand Clause	1 January 2027
Amendments to HKFRS 10 and HKAS 28 – Sale or Contribution of Assets between an Investor and its Associate or Joint Venture	To be determined by the HKICPA

HKFRS 18 replaces HKAS 1 Presentation of Financial Statements. While a number of sections have been brought forward from HKAS 1 with limited changes, HKFRS 18 introduces new requirements for presentation within the statement of profit or loss and other comprehensive income, including specified totals and subtotals. Entities are required to classify all income and expenses within the statement of profit or loss and other comprehensive income into one of the five categories: operating, investing, financing, income taxes and discontinued operations and to present two new defined subtotals. It also requires disclosures about management-defined performance measures in a single note and introduces enhanced requirements on the grouping (aggregation and disaggregation) and the location of information in both the primary financial statements and the notes. Some requirements previously included in HKAS 1 are moved to HKAS 8 Accounting Policies, Changes in Accounting Estimates and Errors, which is renamed as HKAS 8 Basis of Preparation of Financial Statements. As a consequence of the issuance of HKFRS 18, limited, but widely applicable, amendments are made to HKAS 7 Statement of Cash Flows, HKAS 33 Earnings per Share and HKAS 34 Interim Financial Reporting. In addition, there are minor consequential amendments to other HKFRS Accounting Standards. HKFRS 18 and the consequential amendments to other HKFRS Accounting Standards are effective for annual periods beginning on or after 1 January 2027 with earlier application permitted. Retrospective application is required. The Group is currently analysing the new requirements and assessing the impact of HKFRS 18 on the presentation and disclosure of the Group's financial statements.

The directors of the Company are in the process of making an assessment of what the impacts of these new standards, amendments to standards and interpretation are expected to be in the period of initial application. So far it has concluded that the adoption of them is unlikely to have a significant impact on the consolidated financial statements.

4. REVENUE

Disaggregation of revenue from contracts with customers by major products or services line for the years is as follows:

	2025 *HK$'000*	2024 *HK$'000*
Revenue from contracts with customers within the scope of HKFRS 15:		
Provision of medical laboratory testing services and health check services	**35,782**	39,158
Sale and distribution of health related and pharmaceutical products	**–**	686
Provision of insurance brokerage services	**37,570**	30,600
Provision of logistic services	**151**	65
	73,503	70,509

The Group derives revenue from the transfer of goods and services over time and at a point in time in the following major product lines and the geographical regions:

For the year ended 31 December	Provision of medical laboratory testing services and health check services		Sale and distribution of health related and pharmaceutical products		Provision of insurance brokerage services		Provision of logistic services		Total	
	2025 *HK$'000*	2024 *HK$'000*	**2025** *HK$'000*	2024 *HK$'000*	**2025** *HK$'000*	2024 *HK$'000*	**2025** *HK$'000*	2024 *HK$'000*	**2025** *HK$'000*	2024 *HK$'000*
Primary geographical markets										
– Hong Kong, China	**35,782**	39,156	**–**	686	**37,570**	30,600	**151**	65	**73,503**	70,507
– The PRC except Hong Kong, China	**–**	2	**–**	–	**–**	–	**–**	–	**–**	2
Segment revenue	**35,782**	39,158	**–**	686	**37,570**	30,600	**151**	65	**73,503**	70,509
Timing of revenue recognition										
Products and services transferred at a point in time	**35,782**	39,158	**–**	686	**37,570**	30,600	**–**	–	**73,352**	70,444
Products and services transferred over time	**–**	–	**–**	–	**–**	–	**151**	65	**151**	65
Total	**35,782**	39,158	**–**	686	**37,570**	30,600	**151**	65	**73,503**	70,509

5. OTHER INCOME AND OTHER GAINS, NET

	2025	2024
	HK$'000	*HK$'000*
Interest income	**8**	464
Government grants *(note a)*	**646**	545
Loss on disposal of property, plant and equipment	**–**	(108)
Loss on written-off of property, plant and equipment	**(5)**	(15,903)
Exchange gains/(losses), net	**7,700**	(11,152)
Compensation income *(note b)*	**13,824**	27,071
Gain on early termination of lease	**–**	2,350
Service income received from a non-controlling interest	**1,267**	2,533
Others	**118**	–
	23,558	5,800

Notes:

(a) During the year ended 31 December 2025, the government grants mainly related to the high technology enterprise subsidies received from the PRC government and Hong Kong Government.

(b) In October 2024, BNCT equipment located at Hainan Province, the PRC was damaged during rainstorm. Accordingly, an impairment loss of approximately HK$52,713,000 (equivalent to RMB48,680,000) was recognised as impairment loss on property, plant and equipment for the year ended 31 December 2024. The Group was an insurance beneficiary for coverage against damages to the equipment incidental to rainstorm and the related compensation would be recognised only when the compensation has been acknowledged by the insurance company. The Group received approximately HK$13,824,000 and HK$27,071,000 from insurance claim during the year ended 31 December 2025 and 2024 respectively and they were recognised as compensation income.

6. SEGMENT INFORMATION

The Group has five operating segments as follows:

Medical and health related services	–	provision of medical laboratory testing services and health check services
Immunotherapy	–	provision of tumor immune cell therapy and health management services
Pharmaceutical products	–	sale and distribution of health related and pharmaceutical products
Insurance brokerage	–	insurance brokerage services
BNCT	–	provision of boron neutron capture therapy treatment services
Others	–	provision of logistic services

The Group's reportable segments are strategic business units that offer different products and services. They are managed separately because each business requires different technology and marketing strategies.

The Group's other operating segments include provision of logistic services, which does not meet any of the quantitative thresholds for determining reportable segments. The information of this operating segment is included in the 'others' column.

Segment profits or losses do not include other income and other gains excluding loss on disposal of property, plant and equipment, loss on written-off of property, plant and equipment and compensation income, unallocated administrative expenses, fair value loss on convertible bonds, unallocated finance costs, and income tax credit. Segment assets do not include the unallocated bank and cash balances, tax recoverable and financial assets at FVOCI. Segment liabilities do not include unallocated borrowings, current and deferred tax liabilities, convertible bonds and derivative financial liabilities.

The Group accounts for intersegment sales and transfers as if the sales or transfers were to third parties, i.e. at current market prices.

Information about operating segment profit or loss, assets and liabilities:

	Medical and health related services HK$'000	Immunotherapy HK$'000	Pharmaceutical products HK$'000	Insurance brokerage HK$'000	BNCT HK$'000	Others HK$'000	Total HK$'000
For the year ended 31 December 2025							
Revenue from external customers	35,782	–	–	37,570	–	151	73,503
Intersegment revenue	1,050	–	–	–	145	–	1,195
Segment (loss)/profit	(28,779)	(31,300)	(596)	3,531	4,466	(641)	(53,319)
Other income and other gains							9,734
Unallocated finance costs							(17,396)
Fair value loss on convertible bonds							(3,163)
Unallocated corporate expenses							(17,553)
Loss before tax							(81,697)
Income tax credit							856
Loss for the year							(80,841)
As at 31 December 2025							
Segment assets	21,174	137,087	628	9,252	486,119	37	654,297
Unallocated corporate assets							48,278
Total assets							702,575
Segment liabilities	29,243	33,407	440	1,597	227,889	180	292,756
Unallocated corporate liabilities							254,074
Total liabilities							546,830

	Medical and health related services HK$'000	Immunotherapy HK$'000	Pharmaceutical products HK$'000	Insurance brokerage HK$'000	BNCT HK$'000	Others HK$'000	Total HK$'000
For the year ended 31 December 2024							
Revenue from external customers	39,158	–	686	30,600	–	65	70,509
Intersegment revenue	455	–	532	–	–	76	1,063
Segment (loss)/profit	(100,150)	(47,963)	(734)	1,752	(33,652)	(720)	(181,467)
Other income and other losses							(5,260)
Unallocated finance costs							(16,922)
Fair value loss on convertible bonds							(24,156)
Unallocated corporate expenses							(24,992)
Loss before tax							(252,797)
Income tax credit							943
Loss for the year							(251,854)
As at 31 December 2024							
Segment assets	26,525	137,127	887	10,310	272,889	34	447,772
Unallocated corporate assets							82,183
Total assets							529,955
Segment liabilities	15,827	3,510	20	1,803	18,050	122	39,332
Unallocated corporate liabilities							248,235
Total liabilities							287,567

Other segment information

Other segment information for the year ended 31 December 2025:

	Medical and health related services *HK$'000*	Immunotherapy *HK$'000*	Pharmaceutical products *HK$'000*	Insurance brokerage *HK$'000*	BNCT *HK$'000*	Others *HK$'000*	Total *HK$'000*
Capital expenditures	**157**	**–**	**–**	**–**	**152,756**	**–**	**152,913**
Amortisation of intangible assets	**–**	**8,090**	**–**	**–**	**30**	**–**	**8,120**
Depreciation of property, plant and equipment	**1,929**	**315**	**–**	**–**	**43**	**6**	**2,293**
Depreciation of right-of-use assets	**1,683**	**1,309**	**–**	**251**	**247**	**2,537**	**6,027**
Loss on written off of property, plant and equipment	**5**	**–**	**–**	**–**	**–**	**–**	**5**
Cost of services sold	**18,471**	**–**	**–**	**30,323**	**–**	**15**	**48,809**
Staff costs	**26,515**	**3,374**	**297**	**3,132**	**7,805**	**738**	**41,861**
Reversal of impairment loss on financial assets, net	**(30)**	**–**	**–**	**–**	**–**	**–**	**(30)**
Write-down of inventories	**–**	**–**	**115**	**–**	**–**	**–**	**115**
Impairment loss on right-of-use assets	**6,731**	**–**	**–**	**–**	**–**	**–**	**6,731**

Other segment information for the year ended 31 December 2024:

	Medical and health related services *HK$'000*	Immunotherapy *HK$'000*	Pharmaceutical products *HK$'000*	Insurance brokerage *HK$'000*	BNCT *HK$'000*	Others *HK$'000*	Total *HK$'000*
Capital expenditures	969	41	–	–	197,897	7	198,914
Amortisation of intangible assets	–	8,080	–	–	–	–	8,080
Depreciation of property, plant and equipment	5,065	1,023	–	–	9	31	6,128
Depreciation of right-of-use assets	3,963	–	101	192	247	2,705	7,208
Loss on written off of property, plant and equipment	15,903	–	–	–	–	–	15,903
Cost of services sold	26,614	–	535	25,357	–	5	52,511
Staff costs	40,350	3,213	778	3,008	5,729	738	53,816
Allowance for impairment loss on financial assets, net	684	–	–	–	–	–	684
Loss on disposal of property, plant and equipment	108	–	–	–	–	–	108
Write-down of inventories	5,089	–	–	–	–	–	5,089
Impairment loss on right-of-use assets	2,584	–	–	–	–	–	2,584
Impairment loss on intangible assets	13,374	–	–	–	–	–	13,374
Impairment loss on property, plant and equipment	–	–	–	–	52,713	–	52,713

Geographical information

The Group's revenue from external customers by location of operations and information about its non-current assets (excluding financial assets at FVOCI) by location of assets are detailed below:

	Revenue		Non-current assets	
	2025	2024	**2025**	2024
	HK$'000	*HK$'000*	***HK$'000***	*HK$'000*
Hong Kong, China	**73,503**	70,507	**25,125**	27,173
The PRC except Hong Kong, China	**–**	2	**571,984**	396,458
	73,503	70,509	**597,109**	423,631

Revenue from major customers:

Revenue from a customer contributing over 10% of the total revenue of the Group is as follows:

	2025	2024
	HK$'000	*HK$'000*
Provision of insurance brokerage services		
Customer	**11,246**	13,903

7. FINANCE COSTS

	2025	2024
	HK$'000	*HK$'000*
Interest expenses on lease liabilities	**536**	638
Interest on other borrowings	**12,143**	5,040
Interest on bank borrowing	**1,865**	1,690
Interest on written put option liability	**6,537**	5,200
Effective interest on convertible bonds	**6,486**	4,354
	27,567	16,922
Less: interest capitalised on qualifying assets	**(8,094)**	–
	19,473	16,922

8. INCOME TAX CREDIT

Income tax has been recognised in profit or loss as follows:

	2025	2024
	HK$'000	*HK$'000*
Current tax		
Hong Kong		
– Provision for the year	**357**	269
Deferred tax	**(1,213)**	(1,212)
	(856)	(943)

Taxation on profits has been calculated on the estimated assessable profits for the year at the applicable rates of taxation prevailing in the countries/places in which the Group operates, based on existing legislation, interpretation and practices in respect thereof.

9. LOSS FOR THE YEAR

The Group's loss for the year is stated after charging/(crediting) the following:

	2025	2024
	HK$'000	*HK$'000*
Amortisation of intangible assets	**8,120**	8,080
Depreciation of property, plant and equipment	**2,293**	6,128
Depreciation of right-of-use assets	**6,027**	7,208
Loss on written-off of property, plant and equipment	**5**	15,903
Fair value loss on convertible bonds	**3,163**	24,156
Operating lease charges		
– Office premises and warehouses	**1,140**	1,665
Staff costs including directors' remuneration		
– Salaries, bonuses and allowances	**49,723**	63,244
– Equity-settled share-based payments	**–**	304
– Retirement benefits scheme contributions	**2,045**	2,231
	51,768	65,779
Auditor's remuneration		
– Audit services	**1,210**	1,380
– Non-audit services	**244**	140
	1,454	1,520
Cost of services sold	**48,809**	52,511
Write-down of inventories (included in cost of sales)	**115**	5,089
(Reversal of)/allowance for impairment loss on financial assets, net	**(30)**	684
Impairment loss on right-of-use assets	**6,731**	2,584
Impairment loss on property, plant and equipment	**–**	52,713
Impairment loss on intangible assets	**–**	13,374

10. DIVIDENDS

The directors of the Company did not recommend payment of any final dividend for the year ended 31 December 2025 (2024: Nil).

11. LOSS PER SHARE

Basic and diluted loss per share is calculated by dividing the loss for the period attributable to owners of the Company by the weighted average number of ordinary shares during the year ended 31 December 2025 and 2024.

	2025	2024
	HK$'000	*HK$'000*
Loss		
Loss for the year for the purpose of calculating basic/diluted loss per share	**(68,778)**	(198,146)

	2025	2024
	'000	*'000*
Number of shares		
Weighted average number of ordinary shares for the purpose of calculating basic/diluted loss per share	**975,731**	968,491

The calculation of the diluted loss per share did not assume the conversion of the Company's convertible bonds as the inclusion would be anti-dilutive for the year ended 31 December 2025 and 2024.

12. TRADE AND OTHER RECEIVABLES, DEPOSITS AND PREPAYMENT

	2025	2024
	HK$'000	*HK$'000*
Trade receivables	**9,681**	11,126
Allowance for impairment loss	**(4,063)**	(4,093)
	5,618	7,033
Rental and other deposits *(Note)*	**56,801**	51,822
Other receivables	**7,137**	14,012
Prepayments	**10,751**	1,991
Cash held in securities trading accounts with stock brokers	**14**	14
	74,703	67,839
Total trade and other receivables, deposit and prepayment	**80,321**	74,872
Analysis as:		
Current assets	**30,641**	25,416
Non-current assets	**49,680**	49,456
	80,321	74,872

Note: Included in rental and other deposits was an amount of HK$49,680,000 (equivalent to Japanese Yen 1,000,000,000) (31 December 2024: HK$49,456,000 (equivalent to Japanese Yen 1,000,000,000), which represented deposit paid to a pharmaceutical company incorporated in Japan in relation to the purchase of BNCT drugs for the use in BNCT cancer treatment center in Hainan, the PRC.

The aging analysis of trade receivables based on the invoice date, and net of allowance, is as follows:

	2025	2024
	HK$'000	*HK$'000*
0 to 90 days	**5,225**	6,447
91 to 180 days	**353**	510
181 to 365 days	**40**	68
Over 365 days	**–**	8
	5,618	7,033

13. CONVERTIBLE BONDS

On 20 December 2022, the Company issued convertible bonds ("**2022 Convertible Bonds**") at the issue price of US$10,000,000 (equivalent to approximately HK$77,800,000) (equal to 100 per cent of the principal amount of the convertible bonds). The bonds are convertible at the option of the bondholders into ordinary shares at the initial conversion price of HK$1.45 per conversion share (subject to adjustments pursuant to the terms and conditions of the 2022 Convertible Bonds, if any) and at the exchange rate of HK$7.85 to US$1.00, and on this basis a maximum number of 54,137,931 conversion shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the 2022 Convertible Bonds in full assuming there is no adjustment to the conversion price. The 2022 Convertible Bonds carry interest at a rate of 8.25% per annum, which is payable half-yearly in arrears on 20 June and 20 December. The maturity date of the 2022 Convertible Bonds is two years from issue date.

On 17 December 2024, the Company and the bondholder entered into a subscription agreement under which the Company agreed to redeem US$4,000,000 (approximately HK$31,400,000) of the principal amount of the 2022 Convertible Bonds and issue the 2024 Convertible Bonds (as defined below).

On 27 December 2024, the Company issued convertible bonds ("**2024 Convertible Bonds**") in the aggregate principal of US$6,000,000 (equivalent to approximately HK$47,100,000), which shall be settled by the way of set-off on a dollar-to-dollar basis against the principal amount of US$6,000,000 of the 2022 Convertible Bonds. The 2024 Convertible Bonds are convertible at the option of the bondholders into ordinary shares at the initial conversion price of HK$1.20 per conversion share (subject to adjustments pursuant to the terms and conditions of the 2024 Convertible Bonds, if any) and at the exchange rate of HK$7.85 to US$1.00, and on this basis a maximum number of 39,250,000 conversion shares of the Company will be allotted and issued upon exercise of the conversion rights attached to the 2024 Convertible Bonds in full assuming there is no adjustment to the conversion price. The 2024 Convertible Bonds carry interest at a rate of 8.25% per annum, which is payable half-yearly in arrears on 20 June and 20 December. The maturity date is two years from issue date. The 2024 Convertible Bonds are guaranteed by Pengbo (Hainan) Medical Technology Co., Ltd. ("**Pengbo Hainan**") (an indirect wholly-owned subsidiary of the Company), Genius Lead Limited (a controlling shareholder of the Company) and Mr. Liu Xiaolin ("**Mr. Liu**") (executive director and chairman of the Company).

The modification which amended the initial conversion price to HK$1.20 per conversion share was considered to be a substantial modification of the 2022 Convertible Bonds and accordingly the original 2022 Convertible Bonds were derecognised and the 2024 Convertible Bonds were recognised as a new financial liability. Fair value loss on the deferred "day 1" losses on 2022 Convertible Bonds of approximately HK$26,993,000 was recognised in profit or loss during the year ended 31 December 2024.

The issue of convertible bonds have been split between the liability and derivative components and the movements during the year are as follows:

	HK$'000
Liability component at 1 January 2024	53,877
Interest expenses	4,354
Interest paid	(3,238)
Deferred "day 1" losses recognised on the 2022 Convertible Bonds	26,993
Reclassified to borrowings	(31,400)
Reclassified to accruals	(3,418)
Derecognised the 2022 Convertible Bonds	(47,100)
Issuance of the 2024 Convertible Bonds	47,407
Derivative component	(5,230)
Transaction cost related to liability component	(610)
Liability component at 31 December 2024 and 1 January 2025	**41,635**
Interest expenses	**6,486**
Interest paid	**(3,853)**
Liability component at 31 December 2025	**44,268**

	Liabilities *HK$'000*
Derivative component at 1 January 2024	3,916
Derecognition and fair value loss of convertible bonds	(3,144)
Derivative component upon issuance of 2024 Convertible Bonds	5,230
Derivative component at 31 December 2024 and 1 January 2025	**6,002**
Fair value loss for the year	**3,163**
Derivative component at 31 December 2025	**9,165**

The interest charged for the year ended 31 December 2025 is calculated by applying an effective interest rate of 16.0% (2024: 15.0%) to the liability component.

As of the initial recognition of the 2024 Convertible Bonds, the directors of the Company, with the assistance of an external valuer, estimated that the fair value of the 2024 Convertible Bonds as at 27 December 2024 to be approximately HK$47,407,000 by using the discounting cash flow method and binomial option pricing model to measure the liability component and derivative component respectively.

The directors of the Company estimated that the fair value of the liability component of the 2024 Convertible Bonds as at 31 December 2025 to be approximately HK$44,621,000 (2024: HK$42,211,000). This fair value has been estimated by discounting the future cash flows at the market interest rate and classified as level 3 fair value measurement.

The derivative financial asset and derivative financial liability are embedded in the convertible bonds, which is the call option and the conversion option respectively. Each derivative component is measured at its fair value at the date of issue and at the end of each reporting period. The fair values are estimated using Binomial Option Pricing Model (level 3 fair value measurement). The key assumptions adopted are as follows:

	31 December 2025	31 December 2024
Closing share price *(HK$)*	**0.79**	0.51
Weighted average exercise price *(HK$)*	**1.20**	1.20
Expected volatility	**105.21%**	95.55%
Expected life	**0.99**	1.99
Risk free rate	**2.15%**	3.29%
Expected dividend yield	**Nil**	Nil

14. DEEMED DISPOSAL AND WRITTEN PUT OPTION LIABILITY

On 8 December 2023, the Company, Shanghai Longyao Biotech Company Limited ("**Shanghai Longyao**"), an indirect non-wholly-owned subsidiary of the Company and 宜興環科園產發股權投資合夥企業(有限合夥) (in English, for identification purpose only, Yixing Huanke Product Development Equity Investment Enterprise (Limited Partnership) (the "**Yixing Huanke**") entered into a capital injection agreement (the "**Capital Injection Agreement**"), pursuant to which, the Yixing Huanke had agreed to acquire approximately 5.35% effective shareholding in Shanghai Longyao through capital injection to Shanghai Longyao in the amount of RMB48,000,000.

As part of the Capital Injection Agreement, Yixing Huanke was granted a put option ("**Put Option**"), whereby Yixing Huanke can request Shanghai Longyao to repurchase all Yixing Huanke's equity interest in Shanghai Longyao at its discretion under certain conditions at an exercise price of RMB48,000,000 (equivalent to approximately HK$51,337,000) plus 6.0% interest per annum. The capital injection was completed on 19 February 2024. As a result of this transaction, a put option liability of approximately RMB33,383,000 (equivalent to approximately HK$36,247,000) is recognised in the consolidated financial statement based on the present value of the exercise price of RMB48,000,000 plus 6% interest rate per annum, and on the assumption that the Put Option will be redeemable at 31 December 2027.

Upon the completion of the capital injection, Shanghai Longyao remains as a subsidiary of the Group.

The Group was deemed to have disposed of approximately 1.87% of Shanghai Longyao from 68.13% to 66.26% (the "**Deemed Disposal**"). A gain of approximately RMB44,297,000 (equivalent to approximately HK$48,097,000) from the Deemed Disposal was recognised within equity in "other reserve".

A written put option liability of approximately RMB33,383,000 (equivalent to approximately HK$36,247,000) was initially recognised at its fair value in the consolidated statement of financial position, with a corresponding entry of the same amount recognised within equity "other reserve". Its fair value is based on the present value of the exercise price of RMB48,000,000 (equivalent to approximately HK$52,337,000) plus 6% interest rate per annum, by applying a discount rate of 15.79%, and on the assumption that the put option will be redeemable at 31 December 2027. The written put option liability was denominated in RMB and classified under non-current liabilities.

Gain on the Deemed Disposal for the year ended 31 December 2024 was calculated as follows:

	HK$'000
Proceeds received from the capital injection	52,337
Less: recognition of non-controlling interest	(4,021)
Gain on the Deemed Disposal	48,316

Set out below is the summary of the impact on other reserves for the year ended 31 December 2024 in respect of the Deemed Disposal and the written put option liability:

	HK$'000
Gain on the Deemed Disposal	48,316
Initial recognition of the written put option liability	(36,247)
	12,069

Net cash inflow from Deemed Disposal of approximately HK$52,337,000 represents proceeds received from the capital injection for the year ended 31 December 2024.

The movements for the written put option liability during the years are as follows:

	2025	2024
	HK$'000	*HK$'000*
At 1 January	**40,480**	–
Recognition of written put option liability	**–**	36,247
Interest on written put option liability	**6,537**	5,200
Exchange difference	**2,258**	(967)
At 31 December	**49,275**	40,480

15. TRADE AND OTHER PAYABLES AND ACCRUALS

	2025	2024
	HK$'000	*HK$'000*
Trade payables	**33,704**	7,353
Accruals	**27,388**	20,353
Contract liabilities	**2,983**	1,986
Other payables	**24,966**	18,401
	89,041	48,093

The ageing analysis of trade payables based on the date of invoice date, is as follows:

	2025	2024
	HK$'000	*HK$'000*
0 to 90 days	**30,147**	4,883
91 to 180 days	**2,660**	1,549
181 to 365 days	**142**	166
Over 365 days	**755**	755
	33,704	7,353

16. BORROWINGS

	2025	2024
	HK$'000	*HK$'000*
Bank borrowings	**156,132**	25,981
Other borrowings	**88,401**	80,047
Loan from a financial institution	**6,000**	–
Convertible loans *(Note)*	**43,960**	7,893
Loans from a controlling shareholder	**43,519**	24,772
	338,012	138,693
Analysed as:		
Current portion	**195,931**	138,693
Non-current portion	**142,081**	–
	338,012	138,693

Note:

Included in the convertible loans was an amount of approximately HK$33,434,000 (equivalent to RMB30,000,000) which represented a convertible loan that will be converted into shares in Dynamic Healthcare Holdings Limited ("**Dynamic Healthcare**"), an indirect wholly-owned subsidiary of the Company, by Shenzhen BGI Songhe Biotechnology No. 1 Private Venture Capital Investment Fund Partnership (Limited Partnership) (深圳市華大松禾生科一號私募創業投資基金合夥企業(有限合夥)) ("**BGI Songhe**").

On 11 July 2025, the Company together with Dynamic Healthcare and its subsidiary, Pengbo (Hainan), among others, entered into convertible loan agreement, warrant agreement and investment agreement for investment by BGI Songhe. Under the investment, BGI Songhe shall advance a loan of RMB30,000,000 in to Pengbo (Hainan) and Pengbo (Hainan) shall repay the loan of RMB30,000,000 to BGI Songhe upon completion of necessary filing with the relevant PRC government authorities in respect of overseas direct investment by PRC entities. BGI Songhe shall then subscribe for shares in Dynamic Healthcare. BGI Songhe will hold a maximum of 6.25% of the issued share capital of Dynamic Healthcare as enlarged by the issue of the warrant shares and the shares to be issued to Jiabao Zhongzhi (Hainan) Hospital Management Partnership (Limited Partnership) ("**Jiabao Zhongzhi**") (the platform of the share award scheme of Pengbo (Hainan)). For details, please refer to the announcements of the Company dated 11 July 2025 and 8 September 2025.

The range of interest rates of the Group's borrowings for the year ended 31 December were as follows:

	2025	2024
Bank borrowings	**LPR less 0.11% or 3.45% – 4.60%**	LPR less 0.45% or 3.45% – 3.85%
Other borrowings	**0% – 12%**	6% – 12%
Loan from a financial institution	**18%**	N/A
Convertible loans	**0%**	0%
Loans from a controlling shareholder	**10% – 12%**	10%

17. EVENTS AFTER THE REPORTING PERIOD

On 20 February 2026, convertible bonds in the aggregate principal amount of US$35,000,000 (the "**2026 Convertible Bonds**") were issued by the Company to Wealth Strategy Holding Limited (the "**Subscriber**") pursuant to the conditional subscription agreement dated 29 December 2025 entered into between the Company and the Subscriber. The maturity date of the 2026 Convertible Bonds is 20 February 2030. For details, please refer to the Company's circular and announcement dated 22 January 2026 and 20 February 2026 respectively.

As a result of completion of the issue of the 2026 Convertible Bonds on 20 February 2026 and in accordance with the terms and conditions of the 2024 Convertible Bonds, the conversion price of the 2024 Convertible Bonds is adjusted from HK$1.20 per Share to HK$1.11 per Share and the maximum number of Shares to be issued by the Company upon conversion of the 2024 Convertible Bonds in full is 42,432,432 Shares, with effect from 20 February 2026, being the date of completion of the issue of the 2026 Convertible Bonds. Save for such adjustment, all other terms of the 2024 Convertible Bonds remain unchanged. For details, please refer to the Company's announcement dated 20 February 2026.

MANAGEMENT DISCUSSION AND ANALYSIS

FINANCIAL REVIEW

During the year ended 31 December 2025 (the "**FY2025**"), the Group is principally engaged in the provision of medical laboratory testing services and health check services in Hong Kong, provision of tumor immune cell therapy and health management services in the PRC, provision of BNCT services in the PRC, sales and distribution of health related and pharmaceutical products in the PRC and Hong Kong and provision of insurance brokerage services in Hong Kong.

Revenue

The Group's revenue for FY2025 increased by 4.2% to approximately HK$73,503,000, compared to approximately HK$70,509,000 for the year ended 31 December 2024 (the "**FY2024**"). The growth was driven primarily by robust growth in revenue in the insurance brokerage services segment, which was partially net off by a decline in revenue in the medical laboratory testing and health check services segment.

Provision of medical laboratory testing services and health check services

The Group continues to offer a wide spectrum of medical laboratory testing services and quality health check diagnostic services in Hong Kong. The services of this segment were being delivered through two medical laboratories and three health check centres established in Hong Kong.

Revenue from the provision of medical laboratory testing and health check services decreased by 8.6% to approximately HK$35,782,000 in FY2025 from approximately HK$39,158,000 in FY2024, which was mainly attributable to lower demand as public health conditions stabilised, leading to reduced demand for routine testing and preventive health checks by individuals and corporations.

Provision of tumor immune cell therapy services

Shanghai Longyao focused on tumor immune cell therapy in the PRC, and received approval in January 2021 from China's National Medical Products Administration ("**NMPA**") to commence a Phase I clinical trial for LY007 Cellular Injection. This therapy is the PRC's first CD20-targeted autologous chimeric antigen receptor T-cell ("**CAR-T**") treatment approved for clinical trials. LY007 Cellular Injection, a Class 1 investigational new drug, incorporates Shanghai Longyao's patented OX40 costimulatory molecule to enhance T-cell activation for treating relapsed or refractory CD20-positive B-cell non-Hodgkin lymphoma ("**B-NHL**"). As at the date hereof, the Phase I clinical trial, with a total of 13 individuals with B-NHL undergoing reinfusion of LY007 Cellular Injection across low, medium and high dose group, has been completed successfully. The preparation work for Phase II clinical trial has been initiated and the Phase II clinical trial is expected to commence in late 2026. No revenue from this segment was generated during FY2025.

Sale and distribution of health related and pharmaceutical products

The sales and distribution of health-related and pharmaceutical products segment generated approximately HK$686,000 in revenue in FY2024, which primarily represented the clearance of remaining inventory. For FY2025, no revenue was generated from this segment as the Group made a strategic decision to reallocate limited resources toward other higher-margin and higher-growth segment (i.e. BNCT).

*Boron neutron capture therapy ("**BNCT**") cancer treatment centre*

Pengbo (Hainan) entered into a site admission and investment agreement with the Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (the "**Administration**") in February 2022. Pursuant to the agreement, Pengbo (Hainan) has committed to build and operate a cancer treatment center (the "**BNCT Center**") by adoption of the accelerator-based BNCT system – NeuCure®, covering the cyclotron accelerator, dose calculation program and related medical device for BNCT treatment.

The structural construction of the facility was completed in December 2023. The arrival of the BNCT system and its peripheral parts in Hainan was completed in February 2024. Installation of the BNCT system started in May 2024. In October 2024, Hainan was severely affected by Typhoon "Trami", which caused flooding in Hainan, the PRC. Therefore, the construction works of the BNCT Center were significantly impacted in FY2024. In FY2025, the construction and renovation of the BNCT center progressed to the final stage, completing the necessary preparation work ahead of its trial operations in the first quarter of 2026. No revenue from this segment was generated during FY2025.

Provision of insurance brokerage services

The revenue of provision of insurance brokerage services segment increased from approximately HK$30,600,000 for FY2024 to approximately HK$37,570,000 for FY2025. It represented an increase of 22.8% as compared with FY2024. The increase was primarily driven by an expanded sales network and distribution channels, alongside a growing base of high-end customers.

Provision of logistics services

The Group has been providing testing materials and specimens logistics services for local clinics and other corporate clients. The revenue of logistics services had increased markedly from approximately HK$65,000 for FY2024 to approximately HK$151,000 for FY2025. It represented an increase by 1.3 times as compared with FY2024 due to the increase in demand on testing materials and specimen logistics services.

Gross profit/(loss) and gross profit/(loss) margin

The Group achieved a gross profit of approximately HK$7,726,000 for FY2025, representing an improvement from the gross loss of approximately HK$4,940,000 recorded for FY2024. This positive shift resulted in a gross profit margin of approximately 10.5% for FY2025, compared to a gross loss margin of approximately 7.0% for FY2024. The enhanced performance was primarily driven by a significant reduction in inventory write-offs, which decreased from approximately HK$5,089,000 in FY2024 to approximately HK$115,000 in FY2025.

Selling and distribution expenses

Selling and distribution expenses for the FY2025 were approximately HK$8,314,000, representing approximately 29.4% decrease as compared to approximately HK$11,774,000 for FY2024. The decrease was primarily due to reduced staff costs during FY2025.

Administrative expenses

Administrative expenses mainly consisted of staff costs, legal and professional fees, depreciation of right-of-use assets and amortisation of intangible assets. For FY2025, administrative expenses were approximately HK$58,129,000, representing approximately 40.8% decrease as compared to approximately HK$98,141,000 for FY2024, which was mainly attributable to reduced staff cost of approximately HK$6,342,000 and one-off legal claim of approximately HK$22,000,000 incurred in FY2024.

Research and development cost

Research and development costs for FY2025 were approximately HK$17,201,000, representing approximately 48.4% decrease from approximately HK$33,309,000 for FY2024. The decrease was primarily due to lower expenses in the later stage of Phase I clinical trial for tumor immune cell therapy of Shanghai Longyao.

Impairment loss on right-of-use assets

The Group acquired DVF Holdco (Cayman) Limited ("**DVF**") and its subsidiaries (the "**DVF Group**") in 2015. DVF Group is engaging in provision of laboratory testing services and health check services.

Due to the intensified market competition and weakened consumption sentiments in the medical laboratory testing services and health check services in Hong Kong, revenue of laboratory testing and health check services has experienced lower sales than expected by the management of the Group. The performance of the DVF Group does not meet with the forecast set forth in the business plan and a net loss was recorded. As a result, the business of the DVF Group was considered an indication of impairment of non-current assets, attributable to the acquisition of the DVF Group.

During FY2024, the Directors assessed the recoverable amount arising from the DVF Group with reference to the valuations performed by an independent qualified professional valuer on goodwill, intangible assets, right-of-use assets and property, plant and equipment, the Group recorded an impairment loss on intangible assets and right-of-use assets arising from the DVF Group of approximately HK$13,374,000 and HK$2,584,000 respectively and were fully impaired.

During FY2025, the Group further recorded impairment loss on right-of-use assets of HK$6,731,000 arising from the new lease contracts signed during the year for the operation of DVF Group.

Finance costs

For FY2025, the gross finance costs increased to approximately HK$27,567,000 from approximately HK$16,922,000 for FY2024. The increase was mainly attributable to the finance costs arising from additional bank borrowings and other borrowings for the Group's working capital and construction work for BNCT Center. For FY2025, finance costs of HK$8,094,000 had been capitalised on qualifying assets arising from interest expenses of loans specifically used for the construction of the BNCT center. No finance costs were capitalised for FY2024.

Loss for the year

The Group recorded a net loss of approximately HK$80,841,000 for FY2025, representing a 67.9% decrease compared to approximately HK$251,854,000 for FY2024. The significant improvement in operating performance is mainly attributable to (i) the receipt of an insurance claim as compensation income of approximately HK$13,824,000 in FY2025 in relation to the damages to construction site in Hainan by a rainstorm happened in the FY2024; (ii) a decrease in research and development costs from the immunotherapy segment; (iii) reduced operating expenses resulting from successful implementation of costs control measures and (iv) the absence of one off impairment loss on property, plant and equipment and intangible assets in FY2025, which were recorded in FY2024.

BUSINESS REVIEW

Issue of convertible bonds under specific mandate

On 29 December 2025, the Company entered into a subscription agreement with Wealth Strategy Holding Limited (the "**Subscriber**"), pursuant to which the Company has conditionally agreed to issue, and the Subscriber has conditionally agreed to subscribe for, convertible bonds in an aggregate principal amount of US$35,000,000 (equivalent to approximately HK$272,300,000). The issuance of the convertible bonds was completed on 20 February 2026 and the Company has received US$35,000,000 as the proceeds from the issuance of convertible bonds. Details were disclosed in the announcements and circular of the Company dated 29 December 2025, 22 January 2026 and 20 February 2026.

The BNCT System successfully performed its first beam emission

The Group's flagship project at Hainan, BNCT Center achieved significant progress on 20 November 2025. The BNCT System – NeuCure® neutron irradiation system, successfully performed its first beam emission and has officially entered the final clinical commissioning phase, marking an important milestone in the progression of the project and laying a solid foundation for the future operation of the BNCT Center.

The successful beam emission verifies that the various parameters of the core components of the system have met design specifications, marking the formal transition of the project from equipment installation to beam commissioning. This key milestone lays a solid foundation for subsequent core tasks such as precise neutron flux rate control, beam physics verification, and biological effect assessment. It also ensures that the equipment can proceed with clinical treatment to a high standard as planned, providing cancer patients with safe and precise BNCT services.

Granting of loans by banks to subsidiaries to the company

During the year ended 31 December 2025, Hainan Rural Commercial Bank Co., Ltd. Qionghai Sub-Branch agreed to provide Pengbo (Hainan) with a loan in the principal amount of up to RMB180,000,000 and Industrial and Commercial Bank of China Limited, Shanghai JingAn Sub-branch agreed to provide Shanghai Longyao with a loan in the principal amount of up to RMB5,000,000. These loans were both unconditionally and irrevocably guaranteed by the Company and Mr. Liu Xiaolin (executive director and chairman of the Company) for the due and punctual performance of the obligations under the loan agreements, including payment of all sums due and payable by Pengbo (Hainan) and Shanghai Longyao thereunder.

Strategic Investment by BGI Songhe

On 11 July 2025, the Company together with Dynamic Healthcare and Pengbo (Hainan), among others, entered into convertible loan agreement, warrant agreement and investment agreement for investment by BGI Songhe. Under the investment, BGI Songhe shall advance a loan of RMB30,000,000 in to Pengbo (Hainan) and Pengbo (Hainan) shall repay the loan of RMB30,000,000 to BGI Songhe upon completion of necessary filing with the relevant PRC government authorities in respect of overseas direct investment by PRC entities. BGI Songhe shall then subscribe for shares in Dynamic Healthcare. BGI Songhe will hold a maximum of 6.25% of the issued share capital of Dynamic Healthcare as enlarged by the issue of the warrant shares and the shares to be issued to Jiabao Zhongzhi. For details, please refer to the announcements of the Company dated 11 July 2025 and 8 September 2025. As at the date of this announcement, Pengbo Hainai has obtained the loan of RMB30,000,000.

Sales and production of BNCT drug, STEBORONINE®:

In May 2025, the Company, Pengbo (Hainan), and STELLA PHARMA CORPORATION signed a memorandum of understanding to further expand their collaboration in China on the BNCT drug STEBORONINE® and to strengthen the Company's presence in the BNCT industry. This collaboration builds upon the construction of the BNCT Cancer Treatment Centre in the Boao Lecheng International Medical Tourism Pilot Zone of Hainan Free Trade Port, PRC, introducing boron drugs for BNCT implementation and commercialisation. The parties will jointly pursue NMPA approval for STEBORONINE®, facilitate its import from Japan under the Hainan Preferential Policy, and support its launch in China, specifically for application at the BNCT Cancer Treatment Centre. STELLA PHARMA CORPORATION will transfer manufacturing technology for STEBORONINE® 9000 mg/300 mL for infusion (the "**Licensed Product**") formulations and grant its exclusive rights of license to manufacture and sell the Licensed Product in the PRC to the Company. Furthermore, plans are underway to localise production through additional licensing cooperation, enabling large-scale manufacture and sales of Licensed Product. This initiative will accelerate the Group's upstream development in the BNCT industry, enhance its future competitiveness, and promote wider adoption of BNCT cancer treatment across multiple cities in the PRC.

Cooperation with insurance company on BNCT Medical Insurance Product

The Company, AXA China Region Insurance Company (Bermuda) Limited, and reinsurance companies have entered into a memorandum of understanding in relation to the collaboration on the development of a comprehensive medical insurance product covering BNCT cancer treatment costs and related services. This cooperation aims to enhance public awareness and develop an inclusive medical insurance product covering BNCT cancer treatment costs and related services, and improve its accessibility through inclusive insurance coverage by reducing the financial burden of BNCT therapy for patients.

Inter-Hospital Patient Referral

The Group has entered into cooperation partnership with several hospitals in the PRC, including Huashan Hospital affiliated to Fudan University, Shanghai, Jinshazhou Hospital of Guangzhou University of Chinese Medicine and Peking University Shenzhen Hospital, for cancer patients referral to the BNCT Center. These collaborations aim to enhance public awareness and improve accessibility of BNCT therapy.

Shanghai Longyao's clinical trial results for tumor immune cell therapy services – presented in international conference

The progress results of the Phase I clinical study evaluating LY007 Cellular Injection, has demonstrated promising progress. The Phase I clinical study findings were presented at prestigious US oncology and hematology forums, including the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and the 66th Annual Congress of the American Society of Hematology (ASH). Building on this momentum, the Company was invited in 2025 to share its latest clinical trial results at the 18th International Conference on Malignant Lymphoma (ICML) held in Lugano, Switzerland, and the 30th European Hematology Association (EHA) Congress in Milan, Italy. This progress marks Shanghai Longyao's innovative advancement onto the global stage and reflects its growing international recognition.

OUTLOOK

2025 was a pivotal year for the Group. The Group's two core business segments – BNCT and CAR-T – have both achieved milestone breakthroughs, further solidifying its position as a leading innovator in China's Big Health industry. These mark the successful transition of the Group's strategic blueprint from planning to full implementation, laying a solid foundation for substantial future growth.

In the BNCT segment, the Group advanced preparations in 2025 for the soft opening of the BNCT Center located at the Hainan Boao Lecheng International Medical Tourism Pilot Zone, which officially commenced trial operations in February 2026. This flagship facility will serve as a demonstration centre for the technology and act as the cornerstone for building a nationwide network of BNCT cancer treatment centers across the PRC. Building on its existing hospital ownership, the Group will operate and manage its directly-owned hospitals while actively developing a franchise hospital model. Leveraging its role as the exclusive agent of the BNCT equipment and consumables in the Greater China region, the Group will deliver comprehensive one-stop solutions encompassing equipment sales, maintenance services, centre design, turnkey construction, as well as equipment installation and commissioning. In parallel, the Group aims to collaborate with Stella Pharma Corporation to secure NMPA approval for the production and commercialisation of domestically manufactured boron drugs, STEBORONINE®, in the PRC.

In the CAR-T segment, the launch of China's first clinically approved CD20-targeted CAR-T therapy, LY007 Cellular Injection, together with the successful completion of its Phase I clinical trial, marked a major step forward in the transition from research to commercialisation. Phase II trial preparations are progressing on schedule, supported by positive clinical data presented at multiple international oncology and haematology conferences that validated the therapy's promising efficacy and favourable safety profile.

These dual achievements underscore the Group's technological leadership in advanced cancer therapies and its meaningful contribution to the development of China's Big Health industry, in full alignment with national policies promoting innovative oncology solutions and wider access to high-quality medical care.

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

The Group has financed its operations and capital expenditures requirements through internally generated resources, issuance of convertible bonds and bank and other borrowings.

Liquidity and Financial Resources

As at 31 December 2025, the Group held cash and bank balances of approximately HK$12,083,000 (31 December 2024: HK$18,913,000), all of which were principally denominated in Renminbi and Hong Kong dollars. The decrease in cash and bank balances of approximately HK$6,830,000 is mainly due to uses for operational businesses of the Group and the construction of BNCT Center in Hainan, the PRC.

As at 31 December 2025, the Group had outstanding convertible bonds in principal amount of US$6,000,000 (equivalent to approximately HK$47,100,000) with carrying amount of approximately HK$44,268,000 (2024: US$6,000,000 with carrying amount of approximately HK$41,635,000) which carried a fixed interest rate of 8.25% (2024: 8.25%) per annum and is repayable on 27 December 2026 (2024: 27 December 2026) and guaranteed by a subsidiary of the Company, a controlling shareholder of the Company and Mr. Liu (2024: a subsidiary of the Company).

As at 31 December 2025, the Group had (i) secured bank borrowings of approximately HK$141,087,000 (2024: HK$13,259,000), which carried 4.6% (2024: floating interest rate (i.e. loan prime rate for 5-year)) per annum and are a fixed interest rate of repayable within 10 years (2024: 8 years); and (ii) unsecured bank borrowings of approximately HK$15,045,000 (2024: HK$12,722,000) and is repayable within one year (2024: one year).

As at 31 December 2025, the Group had unsecured loans from a controlling shareholder of approximately HK$43,519,000 (31 December 2024: HK$24,772,000) which carried a fixed interest ranged from 10% to 12% (2024: at 10%) per annum and is repayable within one year (2024: one year).

As at 31 December 2025, the Group had secured other borrowings of approximately HK$4,876,000 (2024: HK$5,301,000), which carried a fixed interest rate at 6.7% (2024: 6%) per annum and is repayable within one year (2024: one year).

As at 31 December 2025, the Group had unsecured other borrowings of approximately HK$83,525,000 (2024: HK$74,746,000), which carried interest ranging from 0% to 12% (2024: 8.25% to 12%) per annum and are repayable within one year (2024: one year).

As at 31 December 2025, the Group had secured loan from a financial institution of approximately HK$6,000,000, which carried a fixed interest rate at 18% per annum and is repayable within one year.

As at 31 December 2025, the Group had unsecured and interest free convertible loans of approximately HK$43,960,000 (2024: HK$7,893,000) and are repayable within one year (2024: one year).

The increase in borrowings was mainly due to the use of general working capital and for the development of the BNCT Center.

As at 31 December 2025, total assets of the Group were approximately HK$702,575,000 (2024: HK$529,955,000), whereas total liabilities were approximately HK$546,830,000 (2024: HK$287,567,000). The gearing ratio of the Group, calculated as total liabilities over total assets, was approximately 77.83% (2024: 54.26%). Current ratio (defined as total current assets divided by total current liabilities) was 0.23 times (2024: 0.33 times).

Fortstone International (Hong Kong) Limited ("**Fortstone**"), an indirect non-wholly-owned subsidiary of the Company, is a holder of insurance broker licence under the Insurance Ordinance. As an insurance brokerage company, Fortstone is subject to capital and net assets requirement under the Insurance Ordinance. Fortstone shall maintain a minimum net assets value and a minimum paid up share capital of HK$500,000 at all times. Fortstone oversees its compliance with the capital and net assets requirement by monitoring Fortstone's liquid asset and ranking liabilities at all times to ensure the capital and net assets are well above the minimum required level (i.e. HK$500,000). Fortstone has complied with the capital and net assets requirement during the year ended 31 December 2025.

Capital Structure

As at 31 December 2025 and 2024, the total issued share capital of the Company was HK$97,573,115 divided into 975,731,150 ordinary shares of HK$0.10 each.

SIGNIFICANT INVESTMENT HELD AND PERFORMANCE

As at 31 December 2025, the Group's financial assets at fair value through other comprehensive income amounted to approximately HK$30,660,000 (2024: HK$43,229,000) including an investment in unlisted equity securities (2024: an investment in unlisted equity securities). It mainly consisted an investment of approximately HK$30,660,000 in Pillar Biosciences, Inc. ("**Pillar US**") and Zhengu Dianostics Holdings Limited ("**Pillar China**") (together with Pillar US, "**Pillar**") (which represented 4.36% (2024: 8.16%) of the total asset of the Group as at 31 December 2025). It is the Group's investment strategy to hold the investments in Pillar as long-term investments for the creation of synergy and long term shareholder value.

(i) Investment in Pillar

Pillar is a precision testing company for cancer based in Boston, Massachusetts, the United States of America and Shanghai, the PRC. As at 31 December 2025, the Group held approximately 2.80% (2024: 3.01%) and 3.01% (2024: 3.01%) of equity interests in Pillar US and Pillar China respectively with total fair value of HK$30,660,000 (2024: HK$43,229,000). Based on the latest unaudited consolidated financial statements of Pillar US and Pillar China for FY2025, they recorded loss of approximately US$9,934,000 (2024: US$17,720,000) and US$1,838,000 (2024: US$3,536,000) respectively. A fair value loss on the Group's investment in Pillar of approximately HK$12,569,000 (2024: HK$10,308,000) has been recognised in other comprehensive income for FY2025. No dividend income was received from Pillar for FY2025 (2024: same). As part of the strategic cooperation between the Group and Pillar, a company has been set up by the parties in Hong Kong, namely Asia Molecular Diagnostic Laboratory Limited, which has established a high-standard molecular biology laboratory at the Hong Kong Science and Technology Park and has been providing NGS precision cancer diagnostic services in Hong Kong. The Group believes that the investment in Pillar will create synergies with the Group's medical laboratory testing services and heath check services.

The Group did not hold any significant investment with a market value that account for more than 5% of the Group's total assets as at 31 December 2025.

MATERIAL ACQUISITION AND DISPOSAL OF SUBSIDIARIES AND AFFILIATED COMPANIES

The Group did not have any material acquisition or disposal of subsidiaries and affiliated companies for FY2025.

CAPITAL COMMITMENTS

Capital commitments contracted for at the end of the reporting period but not yet incurred are as follows:

	2025	2024
	HK$'000	*HK$'000*
Property, plant and equipment	**90,866**	122,560

PLEDGED ASSETS

As at 31 December 2025, the Group did not have restricted bank deposits. As at 31 December 2024, the restricted bank deposits denominated in JPY amounting to approximately HK$14,715,000 (equivalent to JPY300,225,000) represented deposits pledged to a bank to secure issuance of an irrevocable letter of credit for the purchase of the BNCT system.

As at 31 December 2025, the Group had secured bank borrowings of approximately HK$141,087,000 (31 December 2024: HK$13,259,000), which were secured by the Group's land use rights and the construction-in-progress in Hainan, the PRC and a joint and several liability guarantee provided by the Company and Mr. Liu (31 December 2024: same) in favour of banking facilities of RMB180,000,000 (2024: RMB50,000,000).

As at 31 December 2025, the Group had bank borrowings of approximately HK$10,030,000 (2024: HK$5,301,000), which were guaranteed by the Company and Mr. Liu.

As at 31 December 2025, the Group had a loan from a financial institution and other borrowings of HK$6,000,000 and HK$4,876,000 respectively which were secured by a charge other the Group's property, plant and equipment of HK$10,496,000, deposit of HK$780,000 and intangible assets of HK$27,027,000. As at 31 December 2024, the Group had other borrowings of HK$5,301,000 which were secured by a charge over the Group's property, plant and equipment of HK$985,000, deposit of HK$1,060,000 and intangible assets of HK$33,620,000.

As at 31 December 2025, the Group had other borrowings of approximately HK$22,289,000 (2024: HK$21,202,000), which was secured by 47% shareholding of a subsidiary of the Company, and guaranteed by the Company and Mr. Liu Xiaolin (2024: same).

CONTINGENT LIABILITIES

As at 31 December 2025, the Group had no material contingent liabilities.

TREASURY POLICY

The Directors will continue to follow a prudent policy in managing the Group's cash balances and maintain a strong and healthy liquidity to ensure that the Group is well placed to take advantage of growth opportunities for the business.

FOREIGN EXCHANGE AND INTEREST RATE EXPOSURE

During FY2025, the business activities of the Group were mainly denominated in Hong Kong dollars and Renminbi. The Group is not exposed to significant foreign exchange risk and has not employed any financial instrument for hedging. When appropriate and at times of interest rate or exchange rate uncertainties or volatility, hedging instruments including interest rate swaps and foreign currency forwards contract will be used by the Group in the management of exposure affecting interest rates and foreign exchange rate fluctuations as appropriate.

EMPLOYEES AND REMUNERATION POLICY

As at 31 December 2025, the Group had a total of 135 (2024: 141) full time employees which were located in Chinese Mainland and Hong Kong. Total staff costs for FY2025 was approximately HK$51,768,000 (FY2024: HK$65,779,000).

The Group remunerates its employees based on their performance, experience and the prevailing market condition. Performance related bonuses are also granted on a discretionary basis. Other employee benefits include mandatory provident fund, insurance and medical coverage, training (including internal training on the Group's policies and procedures, and paid external training organised by third parties), participation in the share option scheme and share award scheme to provide further incentive and rewards to eligible participants who contribute to the success of the Group.

Provident fund benefits are offered to certain full-time employees through a registered scheme under the Occupational Retirement Schemes Ordinance ("**ORSO**") with the Mandatory Provident Fund exemption. The ORSO scheme is administered by trustees, which are independent, with assets held separately from those of the Group. Under the ORSO scheme, the Group contributes 5% of monthly salaries of employees.

The Group operates a Mandatory Provident Fund Scheme for all qualifying employees in Hong Kong (other than those who are covered under ORSO scheme). The assets of the scheme are held separately from those of the Group, in funds under the control of trustees. The Group contributes 5% of relevant payroll costs to the scheme subject to a maximum of HK$1,500 per month per employee. The employees in the PRC are members of respective state-managed defined contribution retirement benefits scheme operated by the local government. The employer and the employees are obliged to make contributions at a certain percentage of the basic payroll under rules of the schemes. The only obligation of the Group with respect to the retirement benefit schemes is to make the specified contributions.

The total contributions payable to the above schemes by the Group and charged to the consolidated statement of profit or loss for FY2025 were approximately HK$2,045,000 (2024: HK$2,231,000).

EVENTS AFTER THE REPORTING PERIOD

Details of the significant events after the reporting period are set out in note 17 in the notes to the consolidated financial statements in this results announcement.

CORPORATE GOVERNANCE PRACTICES

The Board believes that corporate governance is essential to the success of the Company. The Board is committed to maintaining corporate governance with high standard and ensuring compliance of the legal and regulatory requirements. The Company has put in place governance practices with emphasis on the integrity, quality of disclosures, transparency and accountability for the shareholders of the Company. Throughout FY2025, the Company has adopted the principles and code provisions set out in the Corporate Governance Code (the "**CG Code**") as set out in Appendix C1 to the GEM Listing Rules, and has complied with the code provisions in the CG Code.

COMPLIANCE WITH CODE OF CONDUCT FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted a code of conduct regarding securities transactions by Directors on terms not less exacting than the required standard of dealings as set out in Rules 5.48 to 5.67 of the GEM Listing Rules. Having made specific enquiry with all Directors, the Company confirmed that all Directors have complied with the required standard of dealings and its code of conduct regarding securities transactions by the Directors during FY2025 and there is no incident of non-compliance.

CHANGE IN BOARD COMPOSITION

On 25 July 2025, Dr. Yin Ye has been appointed as an executive Director.

On 25 July 2025, Mr. Qian Hongji resigned as an independent non-executive Director of the Company and a member of the Audit Committee.

On 25 July 2025, Dr. Zhang Xiao has been appointed as an independent non-executive Director and a member of the Audit Committee.

AUDIT COMMITTEE

The Audit Committee is currently composed of three independent non-executive Directors, namely, Mr. Yan Guoxiang (Chairman of the Audit Committee), and Dr. Guo Yuantao and Dr. Zhang Xiao as members. The Audit Committee has adopted the terms of reference which are in line with the CG Code. The Group's consolidated financial statements for FY2025 have been reviewed by the Audit Committee.

DIVIDEND

The Board does not recommend nor declare any dividend for FY2025 (2024: Nil).

SCOPE OF WORK OF RSM HONG KONG

The figures in respect of the Group's consolidated statement of profit or loss and other comprehensive income for the year ended 31 December 2025, consolidated statement of financial position at 31 December 2025, consolidated statement of changes in equity for the year ended 31 December 2025 and the related notes for the year ended 31 December 2025 as set out in the preliminary announcement of results have been agreed by the Group's auditor, RSM Hong Kong, to the amounts set out in the Group's audited consolidated financial statements for the year ended 31 December 2025. The work performed by RSM Hong Kong in this respect did not constitute an assurance engagement in accordance with Hong Kong Standards on Auditing, Hong Kong Standards on Review Engagements or Hong Kong Standards on Assurance Engagements issued by the Hong Kong Institute of Certified Public Accountants and consequently no opinion or assurance conclusion has been expressed by RSM Hong Kong on this preliminary announcement of results.

PURCHASE, SALE OR REDEMPTION OF SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities during the year ended 31 December 2025.

SUFFICIENCY OF PUBLIC FLOAT

Based on information publicly available to the Company and within the knowledge of the Directors as at the date of this announcement, the Company has maintained the prescribed public float under the GEM Listing Rules.

By order of the Board
China Biotech Services Holdings Limited
Liu Xiaolin
Chairman and Executive Director

Hong Kong, 27 March 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Dr. Huang Song and Dr. Yin Ye; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk for at least 7 days from the date of its publication and on the website of the Company at www.cbshhk.com.